Updates in the Treatment of HR+/HER2- Breast Cancer - Episode 3
Current Practices for Targeted Therapies and Molecular Testing for HR+/HER2- Metastatic Breast Cancer
Panelists discuss how the latest NCCN guidelines for targeted therapies and biomarker testing in advanced/metastatic breast cancer highlight the importance of biomarker-driven approaches, with particular emphasis on the need for next-generation sequencing testing in the first-line setting, the implications of HER2-low classification, and how the recent FDA approval of a PI3K inhibitor may impact testing practices and treatment strategies.
Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
0:00
Stream Type LIVE
Remaining Time -0:00
1x
2x
1.75x
1.5x
1.25x
1x, selected
0.75x
0.5x
Chapters
descriptions off, selected
captions settings, opens captions settings dialog
captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Please briefly mention the latest NCCN guidelines for targeted therapies and associated biomarker testing.
How does biomarker testing differ in advanced/metastatic breast cancer from early-stage disease?
What should be considered when testing in the first line for advanced disease?
Is there a need for next-generation sequencing testing before first-line metastatic disease? (eg, BRCA, PIK3CA, PD-L1, NTRK, microsatellite instability–high/mismatch repair deficiency, high tumor mutational burden)
Will the recent FDA approval of a PI3K inhibitor affect your testing practice?
For a patient whose cancer has progressed, do you obtain a new biopsy or go back to the original sample? Why?
How has immunohistochemistry (IHC) testing changed with the addition of HER2-low to NCCN guidelines?
How are you interpreting IHC staining results for HER2-low?
How are results reported? Are you given a percentage of staining, or are you given the category of HER2-low?